Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > IF THIS DEAL GOES THROUGH........................
View:
Post by RPINVESTOR1 on Oct 23, 2024 7:38pm

IF THIS DEAL GOES THROUGH........................

What is to prevent the PRIVATE COMPANY from selling the assets to a SECOND PRIVATE

COMPANY (same ownership) for say, $300,000., and have the shareholders of Replicel receive a total

payment of only $225,000. (ie. 75%)?
Comment by MetzGER on Oct 24, 2024 5:12am
There you See the Country you live/ invested. canada is a criminal fraud nation.
Comment by RPINVESTOR1 on Oct 24, 2024 7:12am
.....BUT WHAT DO YOU REALLY THINK??????????
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities